Rockefeller Capital Management L.P. Protagonist Therapeutics, Inc Transaction History
Rockefeller Capital Management L.P.
- $34.7 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding PTGX
# of Institutions
228Shares Held
61.3MCall Options Held
19KPut Options Held
107K-
Farallon Capital Management LLC San Francisco, CA5.84MShares$272 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$268 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$246 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$154 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$151 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.28B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...